

FOR IMMEDIATE RELEASE

AIS HealthCare awarded outsourced services category agreement for intrathecal pain pump medications and designated as a 503A provider with Premier.

Dallas, TX – April 30, 2019 – AIS HealthCare has been awarded an outsourced services category agreement for intrathecal pain pump medications and designated as a 503A provider with Premier. Effective April 15, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for sterile, patient-specific intrathecal pain pump medications.

ABOUT AIS Healthcare

As the largest and leading 503A specialty compounding pharmacy, AIS HealthCare has set the new quality standard for intrathecal medications. AIS HealthCare provides sterile, patient-specific intrathecal pain pump medications for the management of intractable chronic pain and spasticity for patients with implanted intrathecal pumps. AIS prepares 100,000+ patient-specific prescriptions annually and serves 27,000+ intrathecal pump patients per year.

AIS HealthCare pharmacy services are supported by comprehensive care management solutions and patient support systems designed to streamline processes, increase efficiencies and optimize outcomes.

"We are excited to be added to the Premier contract. Our unwavering commitment to quality standards and patient safety contribute to our ability to deliver patient-specific intrathecal medications and services for improved health outcomes and a better level of care," stated Simon Castellanos, Chief Executive Officer of AIS HealthCare.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

WHY AIS Healthcare?

- **Innovation** – With a proven, proprietary process that combines Aseptic Processing (AP) with Terminal Sterilization (TS), we've achieved an unprecedented sterility assurance level of 1:1,000,000 (versus 1:1,000 for aseptic only) and extended Beyond Use Date (21-45 days at room temperature) on all patient-specific prescriptions within maximum concentrations.
- **Quality** – Our quality and sterility processes for every patient-specific dispense go above and beyond industry guidelines including 100% 3rd-party testing of all stock solutions for pH, sterility, potency, endotoxins and particulate matter.
- **Safety** – We have an unwavering commitment to safety. AIS is frequently inspected by state and national boards of pharmacy, DEA, and FDA to ensure patient safety. Our most recent FDA inspection had no 483 observations issued.

Contact: Blaine Forshage, Chief Commercial Officer
877.443.4006 or by email <mailto:bforshage@aiscaregroup.com>